HPV E6/E7 RNA in Situ Hybridization Signal Patterns As Biomarkers of Three-tier Cervical Intraepithelial Neoplasia Grade
Overview
Authors
Affiliations
Cervical lesion grading is critical for effective patient management. A three-tier classification (cervical intraepithelial neoplasia [CIN] grade 1, 2 or 3) based on H&E slide review is widely used. However, for reasons of considerable inter-observer variation in CIN grade assignment and for want of a biomarker validating a three-fold stratification, CAP-ASCCP LAST consensus guidelines recommend a two-tier system: low- or high-grade squamous intraepithelial lesions (LSIL or HSIL). In this study, high-risk HPV E6/E7 and p16 mRNA expression patterns in eighty-six CIN lesions were investigated by RNAscope chromogenic in situ hybridization (CISH). Specimens were also screened by immunohistochemistry for p16INK4a (clone E6H4), and by tyramide-based CISH for HPV DNA. HPV genotyping was performed by GP5+/6+ PCR combined with cycle-sequencing. Abundant high-risk HPV RNA CISH signals were detected in 26/32 (81.3%) CIN 1, 22/22 (100%) CIN 2 and in 32/32 (100%) CIN 3 lesions. CIN 1 staining patterns were typified (67.7% specimens) by abundant diffusely staining nuclei in the upper epithelial layers; CIN 2 lesions mostly (66.7%) showed a combination of superficial diffuse-stained nuclei and multiple dot-like nuclear and cytoplasmic signals throughout the epithelium; CIN 3 lesions were characterized (87.5%) by multiple dot-like nuclear and cytoplasmic signals throughout the epithelial thickness and absence/scarcity of diffusely staining nuclei (trend across CIN grades: P<0.0001). These data are consistent with productive phase HPV infections exemplifying CIN 1, transformative phase infections CIN 3, whereas CIN 2 shows both productive and transformative phase elements. Three-tier data correlation was not found for the other assays examined. The dual discernment of diffuse and/or dot-like signals together with the assay's high sensitivity for HPV support the use of HPV E6/E7 RNA CISH as an adjunct test for deciding lesion grade when CIN 2 grading may be beneficial (e.g. among young women) or when 'LSIL vs. HSIL' assignment is equivocal.
Zhang C, Ye G, Wang X, Huang Y, Huang Q, Liao Y Oncol Lett. 2024; 28(4):481.
PMID: 39161330 PMC: 11332576. DOI: 10.3892/ol.2024.14614.
Uchida-Fujii E, Kato Y, Ueno T, Numasawa Y, Yusa S, Haga T Pathogens. 2024; 13(7).
PMID: 39057823 PMC: 11279536. DOI: 10.3390/pathogens13070597.
Xia X, Jiang M, Lin C, Ke R Methods Mol Biol. 2024; 2822:143-156.
PMID: 38907917 DOI: 10.1007/978-1-0716-3918-4_11.
Stolnicu S, Allison D, Praiss A, Tessier-Cloutier B, Momeni Boroujeni A, Flynn J Am J Surg Pathol. 2023; 47(12):1376-1389.
PMID: 37702216 PMC: 10840845. DOI: 10.1097/PAS.0000000000002122.
Rao X, Zheng L, Wei K, Li M, Jiang M, Qiu J Microbiol Spectr. 2023; :e0389622.
PMID: 36809088 PMC: 10101027. DOI: 10.1128/spectrum.03896-22.